1. Home
  2. CLPR vs COCH Comparison

CLPR vs COCH Comparison

Compare CLPR & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Clipper Realty Inc.

CLPR

Clipper Realty Inc.

HOLD

Current Price

$3.11

Market Cap

49.3M

Sector

Real Estate

ML Signal

HOLD

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

HOLD

Current Price

$0.65

Market Cap

49.7M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CLPR
COCH
Founded
2015
1995
Country
United States
United States
Employees
N/A
47
Industry
Real Estate Investment Trusts
Blank Checks
Sector
Real Estate
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
49.3M
49.7M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
CLPR
COCH
Price
$3.11
$0.65
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
72.8K
117.8K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
10.73%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$109,997,000.00
N/A
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
5.82
N/A
52 Week Low
$2.83
$0.36
52 Week High
$4.61
$1.89

Technical Indicators

Market Signals
Indicator
CLPR
COCH
Relative Strength Index (RSI) 46.97 42.40
Support Level $2.88 $0.36
Resistance Level $3.28 $0.74
Average True Range (ATR) 0.14 0.04
MACD -0.01 -0.00
Stochastic Oscillator 25.81 18.20

Price Performance

Historical Comparison
CLPR
COCH

About CLPR Clipper Realty Inc.

Clipper Realty Inc is a self-administered and self-managed real estate company. It acquires, owns, manages, operates, and repositions multifamily residential and commercial properties in the New York metropolitan area, with a portfolio in Manhattan and Brooklyn. It has classified its reporting segments into Residential Rental Properties and Commercial Rental Properties. The company derives its revenue mostly from the Residential segment.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: